Form 4: Kevin Tang Disposes of 372,000 Shares of Singular Genomics Systems, Inc. Following Merger Agreement

Kevin Tang, a director and 10% owner of Singular Genomics Systems, Inc., disposed of 372,000 shares of common stock following a merger agreement where shares were converted to $20.00 per share in cash.

Summary

• On February 21, 2025, Kevin Tang disposed of 372,000 shares of Singular Genomics Systems, Inc. (OMIC) common stock.
• The disposal was a result of the merger agreement dated December 22, 2024, between Singular Genomics Systems, Inc., Singular Genomics Parent, LLC, and Saturn Merger Sub, Inc.
• According to the agreement, all outstanding shares of OMIC common stock were cancelled and converted into the right to receive $20.00 per share in cash.
• The shares were indirectly beneficially owned through Tang Capital Partners, LP (TCP).
• Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP, and therefore has a pecuniary interest in the shares held by TCP.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it primarily reports a transaction related to a merger completion. There are no inherent positives or negatives from this specific filing.

Future Outlook

The document does not contain any specific forward-looking statements beyond the completion of the merger.

Industry Context

This announcement reflects the completion of a merger transaction, which is a common occurrence in the biotechnology industry as companies seek to consolidate resources, technologies, and market positions. Mergers can provide access to new markets, diversify product portfolios, and create synergies that drive growth and innovation.

Comparison to Industry Standards

• It's difficult to compare this specific transaction to industry standards without knowing the specific strategic rationale behind the merger.
• However, mergers in the genomics sector often involve companies with complementary technologies or market access, similar to how Illumina acquired Pacific Biosciences to expand its sequencing capabilities.
• The $20.00 per share valuation would need to be assessed against comparable transactions in the sector to determine if it represents a fair premium for Singular Genomics Systems, Inc. shareholders.

Stakeholder Impact

• Shareholders received $20.00 per share in cash as a result of the merger.
• The merger will likely impact employees, customers, and suppliers of Singular Genomics Systems, Inc., although the specific nature of the impact is not detailed in this document.

Key Dates